Catalyst Pharmaceuticals Files 8-K

Ticker: CPRX · Form: 8-K · Filed: 2025-05-07T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, SEC Filing, Disclosure

TL;DR

Catalyst Pharma filed a routine 8-K on 5/7/25. No major news yet.

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on May 7, 2025, reporting other events and financial statements/exhibits. The filing does not contain specific details on new events or financial figures within the provided text, but indicates a standard reporting update.

Why It Matters

This filing serves as a standard disclosure for Catalyst Pharmaceuticals, Inc., informing stakeholders about significant events or financial updates as required by the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain information that inherently increases risk.

Key Players & Entities

CATALYST PHARMACEUTICALS, INC. (company) — Filer
May 7, 2025 (date) — Date of Report
Delaware (jurisdiction) — State of Incorporation
33134 (zip_code) — Business Address Zip Code

FAQ

What specific events are being reported in this 8-K filing?

The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as item information, but the provided text does not detail the specific nature of these events or statements.

When was this 8-K report filed?

The report was filed on May 7, 2025.

What is the principal executive office address for Catalyst Pharmaceuticals, Inc.?

The principal executive offices are located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134.

What is Catalyst Pharmaceuticals, Inc.'s fiscal year end?

The company's fiscal year ends on December 31st (1231).

Has Catalyst Pharmaceuticals, Inc. had previous names?

Yes, the company was formerly known as CATALYST PHARMACEUTICAL PARTNERS, INC. (name change on 20110215) and Catalyst Pharmaceutical Partners, Inc. (name change on 20060719).

From the Filing

0001193125-25-114926.txt : 20250507 0001193125-25-114926.hdr.sgml : 20250507 20250507162737 ACCESSION NUMBER: 0001193125-25-114926 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250507 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250507 DATE AS OF CHANGE: 20250507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 25921865 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d892793d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2025-05-07 2025-05-07     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 7, 2025     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle     Suite 801     Coral Gables , Florida     33134 (Address of principal executive offices)     (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐     If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On May 7, 2025, the Company issued a press release announcing its results of operations for the three months ended March 31, 2025 and providing a business update. A copy of the press release is attached hereto as Exhibit 99.1.   Item 9.01 Financial Statements and Exhibits.     (d) Exhibits   99.1 &#160